Posted: 3 June 2024
Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce the appointment of five key opinion leaders and clinical oncologists to its Clinical Advisory Board (CAB).
The CAB will provide expert clinical insight and strategic advice, with a particular focus on pancreatic cancer to Amplia as the Company prepares to undertake clinical trials in the US.
The CAB will be chaired by Amplia’s long-standing clinical advisor, Dr Jose Iglesias, who has over 30 years’ experience in clinical development of new oncology drugs. Dr Iglesius, who was responsible for the Phase 3 development of Abrazane in pancreatic cancer, has commented: “I am excited to be working with Amplia to advance their clinical trial program in pancreatic cancer. Narmafotinib, is a promising new drug for a devastating and poorly managed disease, greatly in need of new treatment options.”
Joining Dr Iglesius on the Clinical Advisory Board are leading experts in oncology and drug development, Dr Jordan Berlin, (Vanderbilt-Ingram Cancer Center, Nashville, USA), Dr Mitesh Borad (Mayo Clini, Phoenix, USA), Prof Nick Pavlakis (North Shore Private Hospital, Sydney) and Dr Jason Lickliter (Nucleus Network, Melbourne). Further details about each member of the Clinical Advisory Board can be found on our webiste www.ampliatx.com.
Aplia CEO and Managing Director Dr Chris Burns commented: “We are delighted to have convened this distinguished panel of experts. Each meber brings a depth of experience that weill greatly benefit both the development of narmafotinib in pancreatic cancer and the company more broadly as our clinical strategy matures. This is a significant milestone on the Company’s growth.”
